Q32 Bio Inc. (NASDAQ:QTTB) Receives $72.33 Consensus PT from Analysts

Shares of Q32 Bio Inc. (NASDAQ:QTTB) have earned a consensus recommendation of “Buy” from the seven analysts that are covering the company, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $72.33.

Several research firms have weighed in on QTTB. Raymond James initiated coverage on Q32 Bio in a research note on Thursday, October 24th. They issued a “strong-buy” rating and a $90.00 target price on the stock. Wells Fargo & Company assumed coverage on shares of Q32 Bio in a research report on Wednesday, September 11th. They issued an “overweight” rating and a $95.00 price target on the stock.

Institutional Investors Weigh In On Q32 Bio

Large investors have recently made changes to their positions in the stock. Values First Advisors Inc. acquired a new position in Q32 Bio in the 3rd quarter worth $33,000. Acadian Asset Management LLC acquired a new position in shares of Q32 Bio during the first quarter worth about $62,000. Rhumbline Advisers grew its holdings in shares of Q32 Bio by 11,681.5% during the second quarter. Rhumbline Advisers now owns 7,658 shares of the company’s stock worth $137,000 after buying an additional 7,593 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Q32 Bio in the 2nd quarter valued at approximately $265,000. Finally, Bank of New York Mellon Corp bought a new stake in Q32 Bio in the 2nd quarter valued at approximately $315,000. Institutional investors own 31.32% of the company’s stock.

Q32 Bio Stock Up 0.6 %

Shares of NASDAQ QTTB opened at $48.00 on Thursday. Q32 Bio has a 1 year low of $8.24 and a 1 year high of $53.79. The firm’s 50-day moving average is $45.84 and its 200-day moving average is $34.07. The company has a current ratio of 6.49, a quick ratio of 6.49 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $578.88 million, a PE ratio of -2.08 and a beta of -0.32.

Q32 Bio (NASDAQ:QTTB) last released its earnings results on Thursday, August 8th. The company reported ($1.42) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.42). Equities analysts expect that Q32 Bio will post -12.13 EPS for the current year.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.